DESCRIPTION OF BUSINESS (Details Narrative) - USD ($) |
3 Months Ended | |||
---|---|---|---|---|
Jun. 15, 2021 |
Jul. 31, 2021 |
Jul. 31, 2020 |
Apr. 30, 2021 |
|
Subsidiary, Sale of Stock [Line Items] | ||||
Description of novel products | The Company’s primary focus is Alzheimer’s disease (“Alzheimer’s” or “AD”). With two current and future product candidates, Alzamend aims to bring treatments or cures to market as quickly as possible. The Company’s current pipeline consists of two novel therapeutic drug candidates (collectively, the “Technology”): (i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001 or LiProSal, through two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., as licensor, and (ii) a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing exclusive worldwide license from the same licensor. | |||
Common stock, par value (in dollars per share) | $ 0.0001 | |||
Net proceeds from common stock | $ 2,000,000 | |||
Series A Preferred Stock [Member] | ||||
Subsidiary, Sale of Stock [Line Items] | ||||
Preferred stock, outstanding | 750,000 | |||
IPO [Member] | ||||
Subsidiary, Sale of Stock [Line Items] | ||||
Number of share issued | 2,500,000 | |||
Number of share exercise | 375,000 | |||
Public offering price | $ 5.00 | |||
Net proceeds from common stock | $ 12,900,000 | |||
IPO [Member] | Series A Preferred Stock [Member] | ||||
Subsidiary, Sale of Stock [Line Items] | ||||
Preferred stock, outstanding | 15,000,000 | |||
IPO [Member] | Digital Power Lending [Member] | ||||
Subsidiary, Sale of Stock [Line Items] | ||||
Stock Issued During Period, Shares, Other | 2,000,000 |
X | ||||||||||
- Definition Describes the product information. No definition available.
|
X | ||||||||||
- Definition Represents public offering price. No definition available.
|
X | ||||||||||
- Definition Face amount or stated value per share of common stock. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The cash inflow from the additional capital contribution to the entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Number of shares of stock issued attributable to transactions classified as other. No definition available.
|
X | ||||||||||
- Definition Number of share options (or share units) exercised during the current period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|